Added benefit of saxagliptin as monotherapy is not proven

December 05, 2013

The drug saxagliptin (trade name: Onglyza) has been approved also as monotherapy in Germany since July 2013 for certain adults with type 2 diabetes mellitus. It is an option when drug treatment is needed, but the drug metformin is not tolerated or cannot be used.

In an early benefit assessment pursuant to the Act on the Reform of the Market for Medicinal Products (AMNOG), the German Institute for Quality and Efficiency in Health Care (IQWiG) examined whether saxagliptin offers an added benefit over the current standard therapy. Such an added benefit cannot be derived from the dossier, however, as the manufacturer did not submit any suitable data.

G-BA specified sulfonylurea as appropriate comparator therapy

Saxagliptin in combination with other drugs has already been available in Germany since 2009 and was already assessed by IQWiG as part of the assessment of the established drug market. Since the middle of this year, it can also be used as monotherapy. However, the precondition is that the patient has metformin intolerance or contraindication.

The Federal Joint Committee (G-BA) specified a sulfonylurea (glibenclamide or glimepiride) as appropriate comparator therapy.

No studies for direct comparison

The drug manufacturer did not provide a direct comparative study in its dossier. However, it did conduct a so-called simple adjusted indirect comparison. For this comparison, it used studies that tested saxagliptin or a sulfonylurea versus placebo. The two drugs can then be compared with each other indirectly using placebo as the common comparator. In principle, such an indirect comparison with the studies described can be suitable to prove an added benefit.

Relevant patient group was not studied

However, this was not the case in the dossier on saxagliptin as monotherapy: In none of the eight studies in total, patients were investigated for whom metformin was not an option. Moreover, the duration in some of the studies was too short to draw conclusions on benefit. Finally, in two of the studies, sulfonylureas were not used in compliance with the approval.

No added benefit of saxagliptin could be derived from the dossier because no suitable data were available for a direct or an indirect comparison with sulfonylurea.

G-BA decides on the extent of added benefit

The dossier assessment is part of the overall procedure for early benefit assessments supervised by the G-BA. After publication of the manufacturer's dossier and IQWiG's assessment, the G-BA conducts a commenting procedure, which may provide further information and result in a change to the benefit assessment. The G- BA then decides on the extent of the added benefit, thus completing the early benefit assessment.

An overview of the results of IQWiG's benefit assessment is given by a German-language executive summary. In addition, the website gesundheitsinformation.de, published by IQWiG, provides easily understandable and brief German-language information on saxagliptin.
-end-
The G-BA website contains both general English-language information on benefit assessment pursuant to §35a Social Code Book (SGB) V and specific German-language information on the assessment of saxagliptin. More English-language information will be available soon (Sections 2.1 to 2.6 of the dossier assessment as well as subsequently published health information on informedhealthonline.org).

Institute for Quality and Efficiency in Health Care

Related Metformin Articles from Brightsurf:

A molecule from gut bacteria reduces effect of diabetes medication
The action of metformin, the classic drug used to treat diabetes by stabilizing blood sugar, can be blocked by a molecule from the bacteria in our intestines, a University of Gothenburg study shows.

Metformin treatment linked to slowed cognitive decline
A six-year study of older Australians with type 2 diabetes has uncovered a link between metformin use, slower cognitive decline and lower dementia rates.

Metformin for type 2 diabetes patients or not? Researchers now have the answer
Metformin is the first-line drug that can lower blood sugar levels in type 2 diabetes patients.

An exploratory study of metformin and rapamycin as maintenance therapy
Volume 11, Number 21 of @Oncotarget reported that eligible patients with stable or responding mPDA after 6 months on chemotherapy were randomized 1:1 to metformin alone or with rapamycin, stratified by prior treatment with FOLFIRINOX.

Examining association of preoperative metformin, surgical outcomes in patients with diabetes
Metformin is the most commonly prescribed noninsulin medication for type 2 diabetes and this observational study examined postoperative death and hospital readmission among adults with type 2 diabetes who had a prescription for metformin before major surgery with those who didn't.

Can metformin reduce obesity in children and adolescents?
A new study has shown metformin -- a glucose-lowering drug commonly used to treat diabetes -- to be effective at lowering some measures of obesity in children and adolescents.

Secret behind diabetes drug's benefits revealed
Researchers went into this study with the idea that metformin might communicate with other tissues in the body by causing the secretion of a protein from the liver.

Study shows metformin offers no strength training benefits for seniors
A clinical trial initiated by University of Kentucky researchers argues against the hypothesis that the diabetes drug metformin could help exercising seniors gain more muscle mass.

Diabetes drug study explores cardiovascular risks for patients with kidney disease
Among the 30 million U.S. adults with Type 2 diabetes, 20% have impaired kidney function.

LSU Health research targets metformin as breast cancer prescription
Research conducted by Suresh Alahari, PhD, Professor of Biochemistry and Genetics at LSU Health New Orleans School of Medicine, has found that metformin, a commonly prescribed drug for Type 2 Diabetes, may be effective in treating cancers that lack a protein called Nischarin.

Read More: Metformin News and Metformin Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.